Key result
Static flow conditions increased the area of endocardial fibrosis compared to normal flow via endothelial-to-mesenchymal transition, a process that was ameliorated by losartan treatment.
Why the study?
Endocardial fibroelastosis forms partly through aberrant endothelial-to-mesenchymal transition, but the pathologic triggers remain unknown.
Does losartan reduce endocardial fibroelastosis and endothelial-to-mesenchymal transition in a neonatal rodent model of abnormal flow?
Does losartan reduce endocardial fibroelastosis and endothelial-to-mesenchymal transition in a neonatal rodent model of abnormal flow?
Abnormal flow conditions promote endocardial fibroelastosis via endothelial-to-mesenchymal transition, which can be significantly ameliorated by losartan treatment in a preclinical model.
Answers are grounded in this paper and cite their sources.
Supports losartan investigation in endocardial fibroelastosis; leaves open translation from this neonatal rodent model.
Endocardial fibroelastosis (EFE) is defined by fibrotic tissue on the endocardium and forms partly through aberrant endothelial-to-mesenchymal transition. However, the pathologic triggers are still unknown. In this study, we showed that abnormal flow induces EFE partly through endothelial-to-mesenchymal transition in a rodent model, and that losartan can abrogate EFE development. Furthermore, we translated our findings to human endocardial endothelial cells, and showed that laminar flow promotes the suppression of genes associated with mesenchymal differentiation. These findings emphasize the role of flow in promoting EFE in endocardial endothelial cells and provide a novel potential therapy to treat this highly morbid condition.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied Endocardial fibroelastosis (n=31). Static flow conditions vs. Normal flow conditions was evaluated on Area of fibrosis (p=0.004). Static flow conditions increased the area of endocardial fibrosis compared to normal flow via endothelial-to-mesenchymal transition, a process that was ameliorated by losartan treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: